Renal Cell Carcinoma
Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy
Investigator: Scott Tykodi, M.D., Ph.D.; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01235962
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Investigator: Scott Tykodi, M.D., Ph.D.; Conditions: Metastatic Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01265901
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
Investigator: Shailender Bhatia, M.D.; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01034631
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
Investigator: Dr John Thompson; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01114230
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Investigator: Ajay K. Gopal, MD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01307267
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Investigator: Fred Appelbaum, MD; Conditions: Renal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01120249
Join Us On